SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950142-23-000368
Filing Date
2023-02-13
Accepted
2023-02-13 17:19:31
Documents
15
Period of Report
2023-02-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh230329934_8k.htm   iXBRL 8-K 27522
2 EXHIBIT 99.1 eh230329934_ex9901.htm EX-99.1 22082
3 GRAPHIC image_001.jpg GRAPHIC 2756
  Complete submission text file 0000950142-23-000368.txt   277008

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nrxp-20230213.xsd EX-101.SCH 3958
5 XBRL DEFINITION FILE nrxp-20230213_def.xml EX-101.DEF 26608
6 XBRL LABEL FILE nrxp-20230213_lab.xml EX-101.LAB 36687
7 XBRL PRESENTATION FILE nrxp-20230213_pre.xml EX-101.PRE 25232
9 EXTRACTED XBRL INSTANCE DOCUMENT eh230329934_8k_htm.xml XML 5452
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 23619999
SIC: 2834 Pharmaceutical Preparations